SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 3 analyzed stories

Zura Bio 3Q 2026: Net loss $25.8M, diluted EPS $(0.20) — 10-Q Summary

Zura Bio reported a third-quarter 2026 net loss of $25.8M, wider than the $18M loss a year earlier, with diluted loss per share of $0.20 versus $0.21. The company had no product sales revenue in either period.

Published:

Updated:

What happened

Zura Bio reported a third-quarter 2026 net loss of $25.8M, or $0.20 per share, with no product sales revenue. Research and development costs were $19.5M, and the company ended the quarter with $187.7M in cash.

Global impact / market context

The company is losing money because it spends on research without selling any products yet. Its cash is expected to last through at least the end of 2028, so it does not need new money soon.

What to watch

  1. Check how much cash Zura Bio still has in its next report and whether that runway estimate still holds through 2028. A shorter runway could mean the company needs to raise money.
  2. Watch research and development spending of $19.5M, which is a large share of the $25.8M net loss. Rising spending without product sales widens losses.
  3. Look for any product sales revenue. There were none in either period, so any sales would be a major change in the business.

Affected assets

  • Zura Bio Limited

Evidence